Low molecular weight heparins and direct oral anticoagulants are recommended as effective treatment options for the early and long-term management of cancer-associated venous thromboembolism.
This review highlights that while LMWH is the traditional standard of care for cancer-associated thrombosis, DOACs are now recommended as effective alternatives for patients without high bleeding risk.
Abstract Cancer-associated thrombosis (CAT) is a major cause of death in oncological patients. The mechanisms of thrombogenesis in cancer patients are not fully established, and it seems to be multifactorial in origin. Also, several risk factors for venous thromboembolism (VTE) are present in these patients such as tumor site, stage, histology of cancer, chemotherapy, surgery, and immobilization. Anticoagulant treatment in CAT is challenging because of high bleeding risk during treatment and recurrence of VTE. Current major guidelines recommend low molecular weight heparins (LMWHs) for early and long-term treatment of VTE in cancer patients. In the past years, direct oral anticoagulants (DOACs) are recommended as potential treatment option for VTE and have recently been proposed as a new option for treating CAT. This manuscript will give a short overview of risk factors involved in the development of CAT and a summary on the recent recommendations and guidelines for treatment of VTE in patients with malignancies, discussing also some special clinical situations (e.g. renal impairment, catheter-related thrombosis, and thrombocytopenia).
Katalin Makó (Tue,) conducted a review in Cancer-associated venous thromboembolism (CAT). Low molecular weight heparins (LMWHs) and direct oral anticoagulants (DOACs) was evaluated. Low molecular weight heparins and direct oral anticoagulants are recommended as effective treatment options for the early and long-term management of cancer-associated venous thromboembolism.